A review.The recent article by Cheema et al. titled ′Efficacy and safety of corticosteroids for the treatment of community-acquired pneumonia: A systematic review and meta-anal. of randomized controlled trials′ published in the Journal of Critical Care, is of great interest.The authors performed an updated, rigorous meta-anal. investigating the role of adjunct corticosteroids in patients with community-acquired pneumonia (CAP).The meta-anal., which included 15 RCTs and over 3000 patients, demonstrated that corticosteroids significantly reduced all-cause mortality and also decreased the need for mech. ventilation, vasopressor support, intensive care unit, and hospital length of stay.CAP remains one of the leading causes of hospitalization and death worldwide.Identifying effective ancillary treatments, such as corticosteroids, to improve outcomes is crucial.However, given the small number of trials and patients included, the evidence for this primary outcome should be further verified.It would be feasible to conduct a trial sequential anal. (TSA) of mortality data to establish more robust evidence regarding the effect of corticosteroids on mortality.In conclusion, while the original meta-anal. provides a signal towards a mortality benefit based on available evidence, our addnl. TSA found this to be somewhat equivocal.Future studies should be conducted to explore corticosteroid therapy for CAP, particularly focusing on mortality, to provide more definitive evidence regarding their role in this patient population.